Abstract

Hypoxemia is seen in patients with pulmonary hypertension and hypoxic pulmonary vasoconstriction worsens their clinical condition. However, vasoconstriction is not the only aspect through which hypoxia induces the progression to pulmonary hypertension. Hypoxia‐inducible factor‐1α (HIF‐1α) is a transcription factor responding to hypoxic conditions by regulating hundreds of genes involved in angiogenesis, erythropoiesis, inflammation, and proliferation. We sought to determine the contribution of HIF‐1α in myeloid lineage cells to the pulmonary vascular response to chronic exposure to hypoxia. We generated myeloid‐specific HIF‐1α knockout (MyeHIF1KO) mice by using Cre‐lox P system, and exposed them to hypoxic conditions for 3 weeks to induce pulmonary hypertension. Macrophages from MyeHIF1KO and control mice were used for western blotting, RT‐qPCR, chemotaxis assay, and ATP assay. MyeHIF1KO mice exposed to hypoxia for 3 weeks exhibited a significant reduction in the right ventricular systolic pressure accompanied by a decrease in the ratio of the right ventricular weight to left ventricular weight, muscularization of the small pulmonary arteries, and infiltration of macrophages into the lung and right ventricle compared with control mice. HIF‐1α‐deficient peritoneal macrophages showed less migration toward monocyte chemoattractant protein‐1 and a decrease in intracellular ATP levels. These results indicate that HIF‐1α in macrophages contributes to the progression of pulmonary vascular remodeling and pulmonary hypertension induced by chronic exposure to hypoxic conditions. The inhibition of myeloid‐specific HIF‐1α may be a novel therapeutic strategy for the treatment of pulmonary hypertension.

Highlights

  • The REVEAL registry in 2012 showed that the current 5year survival rate for patients with pulmonary arterial hypertension significantly improved (Benza et al 2012) compared with that reported in the National Institutes of Health Registry in 1991 (D’Alonzo et al 1991)

  • To clarify the role of macrophage Hypoxia-inducible factor-1a (HIF-1a) in the development of pulmonary hypertension, control mice and MyeHIF1KO mice were exposed to hypoxic conditions (10% O2) for 3 weeks

  • We investigated the expression of HIF-1a target genes, such as Glucose transporter 1 (Glut1), Vascular endothelial growth factor a (Vegfa), Platelet derived growth factor B (Pdgfb), Interleukin 1b (Il1b), iNos, and Arginase 1 (Arg1) in macrophages

Read more

Summary

Introduction

The REVEAL registry in 2012 showed that the current 5year survival rate for patients with pulmonary arterial hypertension significantly improved (Benza et al 2012) compared with that reported in the National Institutes of Health Registry in 1991 (D’Alonzo et al 1991). This improvement is due to the recent clinical application of prostacyclin analogues, endothelin receptor blockers, and phosphodiesterase 5 inhibitors to the treatment of pulmonary hypertension (Wu et al 2013). In COMPERA registry, 5-year mortality of pulmonary arterial hypertension is range from 24% (low-risk group) to 68% (high-risk group) (Hoeper et al 2017)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call